We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Strategic Alliance in Cervical Cancer Diagnostics

By Labmedica staff writers
Posted on 11 Apr 2001
A strategic alliance has been formed by Ampersand Medical Corp. More...
(Chicago, IL, USA; www.ampersandmedical.com) and AmeriPath, Inc. (Riviera Beach, FL, USA; www.ameripath.com) for the joint development of new diagnostic technologies and products relating to cervical cancer.

AmeriPath will receive an undisclosed amount of equity in Ampersand as compensation for its development work and will also provide laboratory services for continued research and clinical trials. Ampersand will pay Ameripath for these services. The two companies will work to bring to market several of Ampersand's products. These include its InPath In-Cell test for the human papillomavirus (HPV) through the identification of increased activity of the E6 and E7 oncogenes for HPV and its disposable liquid cell preservation and slide-preparation system that requires no instrumentation.

AmeriPath will purchase and distribute Ampersand's e2 Collector for cervical samples and will conduct a pilot project using Ampersand's Samba telemedicine and image-management system. AmeriPath is a leading U.S. provider of anatomic pathology, cancer diagnostics, and laboratory information services to doctors and hospitals. "AmeriPath will play a vital role in our goal to offer low cost/easy access cancer screening on a global basis,” said Peter P. Gombrich, chairman and CEO of Ampersand.



Related Links:
Ampersand
AmeriPath

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Resorbable Bovine Collagen Membrane
GenDerm
New
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Reusable catheter patients used 35 percent fewer antibiotics compared to their single-use only counterparts. (Photo courtesy of the University of Southampton)

Reusable Intermittent Catheters Reduce Antibiotic Use Without Increasing Urinary Tract Infections

Intermittent self-catheterization, used to empty the bladder several times a day, can leave patients vulnerable to recurrent urinary tract infections and repeated antibiotic use. Reliance on single-use... Read more

Surgical Techniques

view channel
Image: Avvio Medical\'s technology combines microbubble-enhanced acoustic cavitation with smart catheter navigation to precisely target and break down ureteral stones, all without the need for routine stenting or general anesthesia (Photo courtesy of Avvio Medical)

Anesthesia-Sparing System Targets Faster Ureteral Stone Treatment

Ureteral stone care is often delayed by operating room scheduling constraints and growing wait times, leaving a gap between diagnosis and treatment. With no fundamentally new therapeutic approach introduced... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.